|Bid||200.78 x 1100|
|Ask||201.21 x 900|
|Day's Range||196.58 - 202.92|
|52 Week Range||90.57 - 213.94|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 27, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||193.44|
Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Seagen Inc...
Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.